MedTrace Logo

Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

NCT02480777 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-03-05

No results posted yet for this study

Summary

The primary purpose of this research study is to determine the safety of injecting ones own Schwann cells as a supplement along with nerve autograft (eg sural nerve) a few weeks after a severe injury to the sciatic nerve has occurred.

Conditions

  • Sciatic Nerve Injury

Interventions

BIOLOGICAL

Autologous Human Schwann cells

Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).

Sponsors & Collaborators

  • The Miami Project to Cure Paralysis

    collaborator OTHER

  • W. Dalton Dietrich

    lead OTHER

Principal Investigators

  • Allan Levi, MD, PhD · University of Miami

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02480777 on ClinicalTrials.gov